← board
MEOBF
distress 2/10 · well-funded / low risk$1.700%today-20% from 52w high
Revenue
$17M
Liquidity
$131M
Runway
2.6 yrs
Shares 1y
+165%
Price & events
+6.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+9.7%
1M
+0.0%
3M
+6.9%
6M
+75.3%
1Y
+139.4%
2Y
+21.4%
5Y
+0.0%
All
Overview
- Market Cap
- $2.18B
- Enterprise Value
- $2.11B
- Volume
- 0
- 52 Week Range
- $0.97 – $2.12
- Total Shares
- 1.28B
- Float Shares
- 823.99M
- % Held by Insiders
- 36.25%
- % Held by Institutions
- 17.35%
- Beta
- 0.80
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 1,279,967,187 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.